Ultragenyx, Mereo crash on late-stage bone disease failure - Endpoints News
Mereo BioPharma & Ultragenyx's setrusumab fails Phase 3 trials for osteogenesis imperfecta; stocks plummet. Ultragenyx CEO Emil Kakkis "surprised & disappointed" by results.
Search Group
Share To
Comments
About Screade
Screade® Inc. version ec52223, copyright 2016 - 2026
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments